Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
NVCT
Nuvectis Pharma, Inc.
NASDAQCM
Biotechnology
United States
$24.49
▲
+0.12 (+0.49%)
CLOSED
—
OPEN
$24.00
HIGH
$25.19
LOW
$23.96
PREV CLOSE
$24.37
VOLUME
117.2K
0.35x avg
BID / ASK
16.58 / 25.12
spr 8.54
MARKET CAP
$799.5M
DAY RANGE
$23.96
$25.19
P/E (TTM)
—
Fwd -25.5
EPS (TTM)
-1.33
DIV YIELD
—
52W HIGH
$29.28
-16.3%
52W LOW
$5.55
+341.3%
BETA
-0.26
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$24.49
+0.00
(+0.00%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
NVCT
$24.49
▲
+0.49%
Chart
Valuation
Financials
Peers
News
NVCT · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-ON
252 BARS · +266.6% YOY
1-year price chart. Started at 6.68, currently 24.49, up 266.6 percent. Range 5.65 to 28.53 over 252 data points.
2025-09-05
$6.68 → $24.49 (+266.6%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$0.91
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: strong-sell
· peers $0.91 (-96.3%)
Peers:
ACHV
FDMT
CTMX
MNPR
AURA
CBIO
NGNE
ASMB PE29
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$26.4M
-$16.0M
—
$31.7M
2024-12
—
-$19.0M
-$12.2M
—
$18.6M
2023-12
—
-$22.3M
-$16.0M
—
$19.2M
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
ACHV
FDMT
CTMX
MNPR
AURA
CBIO
NGNE
ASMB
MPLT
950160.KQ
NEWS
Recent News (past 14 days)
CALM
10 HEADLINES · LAST 14 DAYS
Nuvectis Pharma To Participate in Upcoming Investor Conferences
GlobeNewswire · 2026-09-03
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Zacks · 2026-08-19
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
GlobeNewswire · 2026-08-04
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Zacks · 2026-07-29
Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator
MT Newswires · 2026-07-23
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
GlobeNewswire · 2026-07-23
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
GlobeNewswire · 2026-07-23
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
TMX Newsfile · 2026-07-14